Botulinum toxin type a (BOTOX) for treatment of migraine

Disease-a-Month

Volumn 48, Issue 5, 2002, Pages 323-335

  Binder, William J ^a   Brin, Mitchell F ^a   Blitzer, Andrew ^a   Pogoda, Janice M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A;

ACETYLCHOLINE RELEASE; ADULT; ARTICLE; CHOLINERGIC SYSTEM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG TOLERANCE; HUMAN; MAJOR CLINICAL STUDY; MIGRAINE; NEUROTRANSMITTER RELEASE; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; RECEPTOR BLOCKING; RISK BENEFIT ANALYSIS;

EID: 0036559133     PISSN: 00115029     EISSN: None     Source Type: Journal    
DOI: 10.1053/mda.2002.24423     Document Type: Article

References (54)

1. Overview of diagnosis and treatment of migraine
2. Migraine. Patterns of healthcare use
3. The economic cost of migraine. Present state of knowledge
4. Migraine prevalence. A review of population-based studies
5. Botulinum toxin: Historical perspective and potential new indications
6. Botulinum toxin: Chemistry, pharmacology, toxicity, and immunology
7. Botulinum toxin: New and expanded indications
8. The management of hyperfunctional facial lines with botulinum toxin: A collaborative study of 210 injection sites in 162 patients
9. Terminal nerve and motor end plate changes in human orbicularis muscle following botulinum A exotoxin injection
10. Response and immunoresistance to botulinum toxin injections
11. Negative antibody response to long-term treatment of facial spasm with botulinum toxin
12. Comparison of therapeutic efficacies of type A and F botulinum toxins for blepharospasm: A double-blind, controlled study
13. Therapeutic use of type F botulinum toxin
14. Use of botulinum toxin type F injections to treat torticollis in patients with immunity to botulinum toxin type A
15. Botulinum toxin F in the treatment of torticollis clinically resistant to botulinum toxin A
16. Variability of the immunologic and clinical response in dystonic patients immunoresistant to botulinum toxin injections
17. Treatment of dystonia
18. Headache and facial pain responsive to botulinum toxin: An unusual presentation of blepharospasm
19. Treatment of myofascial pain with botulinum A toxin
20. Botulinum toxin in the treatment of myofascial pain syndrome
21. Tension headache: Botulinum toxin paralysis of temporal muscles
22. Treatment of tension-type headache by local injection of botulinum toxin
23. Botulinum toxin A, adjunctive therapy for refractory headaches associated with pericranial muscle tension
24. Botulinum toxin type A as prophylactic treatment in chronic tension-type headache
25. Treatment of tension-type headache with botulinum toxin type A: A double-blind, placebo-controlled study
26. Botulinum toxin injection for cervicogenic headache
27. Botulinum toxin type A (BOTOX®) for treatment of migraine headaches: An open-label study
28. Botulinum toxin type A as a migraine preventive treatment
29. The clinical and pathophysiological observations in migraine and tension-type headache explained by integration of vascular, supraspinal and myofascial inputs
30. Recent advances in migraine management
31. Pathophysiology of migraine and tension-type headache
32. The neurobiology of vascular head pain
33. The trigeminovascular system
34. Extracranial vasodilation mediated by vasoactive intestinal polypeptide (VIP)
35. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache
36. Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm
37. Selective location of acceptors for botulinum neurotoxin A in the central and peripheral nervous systems
38. Rhinorrhea is decreased in dogs after nasal application of botulinum toxin
39. Botulinum-A toxin effects on rat jaw muscle spindles
40. Muscle afferent block by intramuscular injection of lidocaine for the treatment of writer's cramp
41. Molecular action of botulinum neurotoxins: Role of acceptors in targetting to cholinergic nerves and in the inhibition of the release of several transmitters
42. Botulinum toxin A blocks glutamate exocytosis from guinea pig cerebral cortical synaptosomes
43. Characterization of the inhibitory action of botulinum neurotoxin type A on the release of several transmitters from rat cerebrocortical synaptosomes
44. Effects of botulinum A toxin on presynaptic modulation of evoked transmitter release
45. Ca2+-dependent noradrenaline release from permeabilized PC12 cells is blocked by botulinum neurotoxin A or its light chain
46. Tetanus and botulinum toxins type A and B inhibit glutamate, gamaaminobuturic acid, aspartate, and met-enkephalin release from synaptosomes
47. Inhibition of neurotransmitter release by clostridial neurotoxins correlates with specific proteolysis of synaptosomal proteins
48. Neuropeptide Y coexists with vasoactive intestinal polypeptide and acetylcholine in parasympathetic cerebrovascular nerves originating in the sphenopalatine, otic and internal carotid ganglia of the rat
49. Calcitonin gene-related peptide: Possible role in formation and maintenance of neuromuscular junctions
50. The placebo effect in acute headache management: Ketorolac, meperidine, and saline in the emergency department